Skip to main content
. Author manuscript; available in PMC: 2021 Apr 10.
Published in final edited form as: Leukemia. 2020 Aug 20;35(4):1064–1072. doi: 10.1038/s41375-020-01010-6

Table 2:

All-Grade, All-Causality TEAEs in ≥10% of Patients and Grade ≥3 Events in All Patients

Grades 1–2, Grade 3, Grade 4, Grade 5, Total
N=32 n (%) n (%) n (%) n (%) N (%)
Hematologic

Decreased platelet count 13 (41) 2 (6) 11 (34) 0 (0) 26 (81)
Decreased neutrophil count 5 (16) 1 (3) 19 (59) 0 (0) 26 (78)
Decreased lymphocyte count 2 (6) 6 (19) 15 (47) 0 (0) 23 (72)
Decreased WBC count 6 (19) 7 (22) 9 (28) 0 (0) 22 (69)
Anemia 12 (38) 5 (16) 0 (0) 0 (0) 17 (53)
Febrile neutropenia 0 (0) 7 (22) 0 (0) 0 (0) 7 (22)
Increased lymphocyte count 3 (9) 1 (3) 0 (0) 0 (0) 4 (12)

Nonhematologic

Nausea 23 (72) 0 (0) 0 (0) 0 (0) 23 (72)
Fatigue 21 (66) 1 (3) 0 (0) 0 (0) 22 (69)
Fever 18 (56) 0 (0) 0 (0) 0 (0) 18 (56)
Hyperglycemia 18 (56) 0 (0) 0 (0) 0 (0) 18 (56)
Diarrhea 15 (47) 1 (3) 0 (0) 0 (0) 16 (50)
ALT increased 6 (19) 5 (16) 4 (13) 0 (0) 15 (47)
AST increased 7 (22) 7 (22) 1 (3) 0 (0) 15 (47)
Cough 13 (41) 0 (0) 0 (0) 0 (0) 13 (41)
Skin disorders 12 (38) 1 (3) 0 (0) 0 (0) 13 (41)
Anorexia 11 (34) 0 (0) 0 (0) 0 (0) 11 (34)
Dyspnea 11 (34) 0 (0) 0 (0) 0 (0) 11 (34)
GI disorders 10 (31) 1 (3) 0 (0) 0 (0) 11 (34)
Upper respiratory tract infection 11 (34) 0 (0) 0 (0) 0 (0) 11 (34)